Quince Therapeutics Inc QNCX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if QNCX is a good fit for your portfolio.
News
-
Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results
-
Quince Therapeutics Launches Scientific Advisory Board
-
Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors
-
Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
-
Quince Therapeutics to Advance Study of EryDex as FDA Lifts Application Hold
Trading Information
- Previous Close Price
- $1.05
- Day Range
- $1.07–1.07
- 52-Week Range
- $0.84–1.72
- Bid/Ask
- $1.05 / $1.11
- Market Cap
- $46.24 Mil
- Volume/Avg
- 9,135 / 71,001
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 32
- Website
- https://www.quincetx.com
Comparables
Valuation
|
Metric
|
QNCX
|
CBAY
|
PLRX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.54 | 12.65 | 1.50 |
Price/Sales | — | 111.01 | 441.50 |
Price/Cash Flow | — | — | — |
Price/Earnings
QNCX
CBAY
PLRX
Financial Strength
|
Metric
|
QNCX
|
CBAY
|
PLRX
|
|---|---|---|---|
Quick Ratio | 7.95 | 10.70 | 17.43 |
Current Ratio | 8.09 | 10.96 | 17.72 |
Interest Coverage | — | −5.27 | −145.34 |
Quick Ratio
QNCX
CBAY
PLRX
Profitability
|
Metric
|
QNCX
|
CBAY
|
PLRX
|
|---|---|---|---|
Return on Assets (Normalized) | −17.37% | −30.06% | −22.68% |
Return on Equity (Normalized) | −21.01% | −51.97% | −24.50% |
Return on Invested Capital (Normalized) | −24.09% | −30.87% | −28.46% |
Return on Assets
QNCX
CBAY
PLRX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zsnvtpfmz | Pqzv | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Qgvzgyqx | Dswsvj | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Btlfngvb | Mxtdr | $97.8 Bil | |
MRNA
| Moderna Inc | Frjjltx | Grgnm | $41.3 Bil | |
ARGX
| argenx SE ADR | Jypykdxr | Mjd | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Drcjcghy | Btcwx | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dgzlckrl | Cwljgvf | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Bshnxbtd | Pntmhgj | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Fnnxykqhr | Xxmvfzv | $12.5 Bil | |
INCY
| Incyte Corp | Zcbfjnks | Ckfbqq | $11.6 Bil |